Impact BioMedical Initiates Bioplastics Research Collaboration with One of World’s Largest Plastic Manufacturers
Document Security Systems (DSS) announced a bioplastics research collaboration through its subsidiary Impact BioMedical. The partnership aims to develop five types of advanced microbial-resistant plastics to combat pathogens like SARS-CoV-2 and E. coli. Daryl Thompson, a noted researcher and twice Nobel nominee, is leading the project, targeting completion in Q4. This initiative leverages GRDG Sciences' expertise and addresses the growing market demand for microbial-resistant consumer products. DSS emphasizes the importance of this research in meeting an increasing consumer awareness of health safety.
- Initiation of a bioplastics research collaboration focused on developing advanced microbial-resistant plastics.
- Collaboration led by Daryl Thompson, a recognized expert in the field.
- Targeting completion of research in Q4, enabling potential global licensing agreements.
- None.
ROCHESTER, N.Y., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Document Security Systems, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating businesses focusing on brand protection technology, blockchain security, direct marketing, healthcare, real estate, and securitized digital assets, today announced its wholly owned subsidiary Impact BioMedical, Inc. (“Impact BioMedical”), through its subsidiary Impact BioLife Science, Inc. (“Impact BioLife”), initiated a bioplastics research collaboration with one of the world’s largest plastic manufacturers. The collaboration is focused on developing five new types of advanced microbial-resistant plastics.
The bioplastics research collaboration builds upon existing research of Daryl Thompson, founder of advance research company, GRDG Sciences, LLC. (“GRDG”), and Impact BioLife’s Director of Scientific Initiatives. Notably, Thompson has been twice nominated for the Nobel Prize for his work in cutting-edge organic and carbohydrate chemistry.
“We are developing antimicrobial plastics for consumer products that control the spread of active pathogens such as SARS-CoV-2, Influenza, E. coli, Staph, and Rhinovirus,” stated Thompson. “We are researching and exploiting key strategies found in the biological realm that can create plastics that are highly beneficial. Under this collaboration, we are specifically looking at solutions for common products such as cups, plates, utensils, plastic bags, and even counter tops, which together represent a significant and timely market opportunity. We are targeting to complete our research and testing phase early in the fourth quarter, setting the stage to quickly move into negotiations for global licensing and royalty agreements.”
GRDG is a specialized research team that focuses on developing solutions for biodefense under the guidelines of the Project BioShield Act, Event 201, and Potomac Institute for Policy Studies.
GRDG performs rapid analysis and research by using advanced algorithms and the most complete databases in the world. The team operates in a lean and efficient manner and when necessary utilizes the top contract research organizations to deliver solid results that are robust and accurate.
GRDG’s Chief Scientific Advisor Dr. Roscoe M. Moore, Jr., the former United States Assistant Surgeon General and former Epidemic Intelligence Service Officer at Centers for Disease Control and Prevention or CDC commented, “Research to date affirms our belief that our bioplastics technology can be a major game changer for a wide variety of consumer products and even beyond.”
“Consumers have a newly heightened awareness of the importance of microbial-resistant products and surfaces, and the patented bioplastics we are developing could provide an extremely effective solution to meet this growing unmet need,” commented Jason Grady, Chief Operating Officer of DSS.
About Impact BioMedical, Inc.
Impact BioMedical, Inc. ("Impact BioMedical") is a wholly owned subsidiary of DSS. Impact BioMedical strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. By tapping into the scientific expertise of GRDG Sciences, LLC, Impact BioMedical pledges to undertake a concerted effort in the R&D, drug discovery and development for the prevention, inhibition, and treatment of neurological, oncological and immuno related diseases. For more information on Impact BioMedical visit http://impbio.com/.
About Document Security Systems, Inc.
DSS is a multinational company operating businesses focused on brand protection technology, blockchain security, direct marketing, healthcare, real estate, and securitized digital assets. Its business model is based on a distribution sharing system in which shareholders will receive shares in its subsidiaries as DSS strategically spins them out into IPOs. Its historic business revolves around counterfeit deterrent and authentication technologies, smart packaging, and consumer product engagement. DSS is led by its Chairman and largest shareholder, Mr. Fai Chan, a highly successful global business veteran of more than 40 years specializing in corporate transformation while managing risk. He has successfully restructured more than 35 corporations with a combined value of
For more information on DSS visit http://www.dsssecure.com.
Investor Contact:
Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
Dave@redchip.com
Safe Harbor Disclosure
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements related to the Company's intended use of proceeds and other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. These risks and uncertainties, many of which are beyond our control, include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of development activities; our ability to attract, integrate and retain key personnel; our need for substantial additional funds; patent and intellectual property matters; competition; as well as other risks described in the section entitled "Risk Factors" in the prospectus and in our other filings with the SEC, including, without limitation, our reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
FAQ
What is the recent collaboration announced by DSS on September 8, 2020?
Who is leading the bioplastics research at DSS?
What pathogens will the new plastics help combat?
When does DSS plan to complete the research for the bioplastics?
What market opportunity does DSS target with its new bioplastics?
